Surrozen, Inc. (NASDAQ:SRZN) Shares Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC grew its holdings in Surrozen, Inc. (NASDAQ:SRZN) by 66.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 110,000 shares of the company’s stock after buying an additional 43,916 shares during the period. Surrozen makes up 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 24th biggest holding. Stonepine Capital Management LLC’s holdings in Surrozen were worth $1,318,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Surrozen during the second quarter valued at approximately $2,080,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen in the second quarter valued at approximately $2,050,000. Finally, CVI Holdings LLC acquired a new stake in shares of Surrozen in the second quarter worth approximately $711,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Stock Performance

Shares of NASDAQ:SRZN traded up $0.36 during trading on Wednesday, reaching $9.74. The stock had a trading volume of 1,991 shares, compared to its average volume of 16,001. The business has a fifty day moving average price of $10.20 and a 200-day moving average price of $9.71. Surrozen, Inc. has a 1-year low of $6.00 and a 1-year high of $16.19.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The firm had revenue of $10.00 million during the quarter. As a group, equities research analysts expect that Surrozen, Inc. will post -7.16 earnings per share for the current fiscal year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.